Pivotal Papers
Advertisement
Advertisement
Trending on BioPharm International
1
Genmab’s Petosemtamab Plus Pembrolizumab Cuts Risk of Death by 50% in Phase 3 Head and Neck Cancer Trial
2
3SBio and Pfizer’s PD-1×VEGF Bispecific Shows Durable PFS Gains in First-Line NSCLC
3
How Lipid-Based Softgels Protect Oral Peptides from Degradation
4
Immatics’ PRAME-Targeted TCR Bispecific IMA402 Shows 32% Response Rate in PRAME-High Tumors
5